Click Therapeutics Acquires Better Therapeutics’ Assets to Enhance Digital Therapeutics Portfolio

Share This Post

Key Highlights

  • Click Therapeutics acquires Better Therapeutics’ assets, including AspyreRx.
  • Advances pipeline in obesity, diabetes, and cardiometabolic diseases.
  • Integration to enhance development of digital therapies for chronic weight management.
  • Focus on innovative features like smart titration and personalized side effect management.
  • Combination of digital and drug therapies for improved patient outcomes.

Source: Business Wire

Notable Quotes

  • “There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” – Rich DeNunzio, Chief Commercial Officer at Click Therapeutics
  • “Click can immediately strengthen AspyreRx by combining the latest engagement technology from our platform with Better’s therapeutic core,” – Han Chiu, Chief Technology Officer at Click Therapeutics

SoHC's Take

Click Therapeutics’ acquisition of Better Therapeutics’ assets marks a significant advancement in the field of digital therapeutics, particularly for obesity and cardiometabolic diseases. By integrating clinically-validated digital therapies like AspyreRx with their AI-enabled platform, Click is positioned to deliver personalized and effective treatment options. This strategic move not only accelerates their development timelines but also strengthens their competitive edge in a rapidly growing market. The focus on smart titration and personalized side effect management highlights Click’s commitment to improving patient outcomes and providing innovative solutions in digital health.

More To Explore

Total
0
Share